Recognition of R&D Expenses and Continuation of R&D Activities
First written in FY2017-Q3. 28 of 31 entries say "Restated". Latest entry: FY2026.
- FY2026Increase in R&D expensesAnnual report
「Total R&D expenses for the fiscal year were ¥11 million. The purchase costs of new ingredients and the costs of quality testing for new ingredients, among other items, were recorded as R&D expenses.」
R&D activities, including the purchase and quality testing of new ingredients, continued, and annual R&D expenses increased from ¥7 million in the previous fiscal year to ¥11 million. - FY2026-H1RestatedAnnual report
「Total R&D expenses for the cumulative consolidated six-month period were ¥5 million. There were no material changes in the status of the Group's R&D activities during the cumulative consolidated six-month period.」
R&D expenses were ¥5 million, and no material changes were reported in the status of R&D activities. - FY2025RestatedAnnual report
「Total R&D expenses for the fiscal year were ¥7 million. The purchase costs of new ingredients and the costs of quality testing for new ingredients, among other items, were recorded as R&D expenses.」
R&D activities, including the purchase and quality testing of new ingredients, continued, bringing annual R&D expenses to ¥7 million. - FY2025-H1RestatedAnnual report
「Total R&D expenses for the cumulative consolidated six-month period were ¥3 million. There were no material changes in the status of the Group's R&D activities during the cumulative consolidated six-month period.」
R&D expenses were ¥3 million, and no material changes were reported in the status of R&D activities. - FY2024Increase in R&D expensesAnnual report
「Total R&D expenses for the fiscal year were ¥8 million. The purchase costs of new ingredients and the costs of quality testing for new ingredients, among other items, were recorded as R&D expenses.」
R&D activities, including the purchase and quality testing of new ingredients, continued, and annual R&D expenses increased from ¥3 million in the previous fiscal year to ¥8 million. - FY2024-Q3RestatedAnnual report
「Total R&D expenses for the cumulative consolidated period ended the third quarter were ¥5 million. There were no material changes in the status of the Group's R&D activities during the cumulative consolidated period ended the third quarter.」
R&D expenses were ¥5 million, and no material changes were reported in the status of R&D activities. - FY2024-Q2RestatedAnnual report
「Total R&D expenses for the cumulative consolidated period ended the second quarter were ¥3 million. There were no material changes in the status of the Group's R&D activities during the cumulative consolidated period ended the second quarter.」
R&D expenses were ¥3 million, and no material changes were reported in the status of R&D activities. - FY2024-Q1RestatedAnnual report
「Total R&D expenses for the cumulative consolidated period ended the first quarter were approximately ¥1 million. There were no material changes in the status of the Group's R&D activities during the cumulative consolidated period ended the first quarter.」
R&D expenses were approximately ¥1 million, and no material changes were reported in the status of R&D activities. - FY2023RestatedAnnual report
「Total R&D expenses for the fiscal year were ¥3 million. The purchase costs of new ingredients and the costs of quality testing for new ingredients, among other items, were recorded as R&D expenses.」
R&D activities, including the purchase and quality testing of new ingredients, continued, bringing annual R&D expenses to ¥3 million. - FY2023-Q3RestatedAnnual report
「Total R&D expenses for the cumulative consolidated period ended the third quarter were ¥2 million. There were no material changes in the status of the Group's R&D activities during the cumulative consolidated period ended the third quarter.」
R&D expenses were ¥2 million, and there were no material changes in the status of R&D activities. - FY2023-Q2RestatedAnnual report
「Total R&D expenses for the cumulative consolidated period ended the second quarter were ¥1 million. There were no material changes in the status of the Group's R&D activities during the cumulative consolidated period ended the second quarter.」
R&D expenses were ¥1 million, and there were no material changes in the status of R&D activities. - FY2023-Q1RestatedAnnual report
「Total R&D expenses for the cumulative consolidated period ended the first quarter were approximately ¥1 million. There were no material changes in the status of the Group's R&D activities during the cumulative consolidated period ended the first quarter.」
R&D expenses were approximately ¥1 million, and no material changes were reported in the status of R&D activities. - FY2022-Q3RestatedAnnual report
「Total R&D expenses for the nine months ended 31 December were ¥4 million. There were no material changes in the status of the Group's R&D activities during the nine months ended 31 December.」
R&D expenses were ¥4 million, and no material changes were reported in R&D activities. - FY2022-Q2RestatedAnnual report
「Total R&D expenses for the six months ended 30 September were ¥2 million. There were no material changes in the status of the Group's R&D activities during the six months ended 30 September.」
R&D expenses were ¥2 million, and no material changes were reported in R&D activities. - FY2022-Q1RestatedAnnual report
「Total R&D expenses for the three months ended 30 June were ¥1 million. There were no material changes in the status of the Group's R&D activities during the three months ended 30 June.」
R&D expenses were ¥1 million, and there were no material changes in the status of R&D activities. - FY2021RestatedAnnual report
「Total R&D expenses for the fiscal year were ¥4 million. The purchase costs of new ingredients and the costs of quality testing for new ingredients, among other items, were recorded as R&D expenses.」
R&D activities, including the purchase and quality testing of new ingredients, continued, bringing R&D expenses to ¥4 million. - FY2021-Q3RestatedAnnual report
「Total R&D expenses for the cumulative consolidated period ended the third quarter were ¥3 million. There were no material changes in the status of the Group's R&D activities during the cumulative consolidated period ended the third quarter.」
R&D expenses were ¥3 million, and no material changes were reported in R&D activities. - FY2021-Q2RestatedAnnual report
「Total R&D expenses for the six months ended 30 September were ¥2 million. There were no material changes in the status of the Group's R&D activities during the six months ended 30 September.」
R&D expenses were ¥2 million, and there were no material changes in the status of R&D activities. - FY2021-Q1RestatedAnnual report
「Total R&D expenses for the three months ended 30 June were ¥1 million. There were no material changes in the status of the Group's R&D activities during the three months ended 30 June.」
R&D expenses were ¥1 million, and there were no material changes in the status of R&D activities. - FY2020RestatedAnnual report
「Total R&D expenses for the fiscal year were ¥4 million. The purchase costs of new ingredients and the costs of quality testing for new ingredients, among other items, were recorded as R&D expenses.」
R&D activities, including the purchase and quality testing of new ingredients, continued. - FY2020-Q3RestatedAnnual report
「Total R&D expenses for the cumulative consolidated period ended the third quarter were ¥3 million. There were no material changes in the status of the Group's R&D activities during the cumulative consolidated period ended the third quarter.」
R&D expenses were ¥3 million, and no material changes were reported in the status of R&D activities. - FY2020-Q2RestatedAnnual report
「Total R&D expenses for the six months ended 30 September were ¥2 million. There were no material changes in the status of the Group's R&D activities during the six months ended 30 September.」
R&D expenses were ¥2 million, and there were no material changes in the status of R&D activities. - FY2020-Q1RestatedAnnual report
「Total R&D expenses for the three months ended 30 June were ¥1 million. There were no material changes in the status of the Group's R&D activities during the three months ended 30 June.」
R&D expenses were ¥1 million, and there were no material changes in the status of R&D activities. - FY2019RestatedAnnual report
「Total R&D expenses for the fiscal year were ¥7 million. The purchase costs of new ingredients and the costs of quality testing for new ingredients, among other items, were recorded as R&D expenses.」
R&D activities, including the purchase and quality testing of new ingredients, continued, bringing annual R&D expenses to ¥7 million. - FY2019-Q3RestatedAnnual report
「Total R&D expenses for the cumulative consolidated period ended the third quarter were ¥5 million. There were no material changes in the status of the Group's R&D activities during the cumulative consolidated period ended the third quarter.」
R&D expenses were ¥5 million, and no material changes were reported in the status of R&D activities. - FY2019-Q2RestatedAnnual report
「Total R&D expenses for the six months ended 30 September were ¥2 million. There were no material changes in the status of the Group's R&D activities during the six months ended 30 September.」
R&D expenses were ¥2 million, and there were no material changes in the status of R&D activities. - FY2019-Q1RestatedAnnual report
「Total R&D expenses for the three months ended 30 June were ¥1 million. There were no material changes in the status of the Group's R&D activities during the three months ended 30 June.」
R&D expenses were ¥1 million, and there were no material changes in the status of R&D activities. - FY2018-Q3RestatedAnnual report
「Total R&D expenses for the nine months ended 31 December were ¥4 million. There were no material changes in the status of the Group's R&D activities during the nine months ended 31 December.」
R&D expenses were ¥4 million, and no material changes were reported in the status of R&D activities. - FY2018-Q2RestatedAnnual report
「Total R&D expenses for the six months ended 30 September were ¥2 million. There were no material changes in the status of the Group's R&D activities during the six months ended 30 September.」
R&D expenses were ¥2 million, and there were no material changes in the status of R&D activities. - FY2018-Q1RestatedAnnual report
「Total R&D expenses for the three months ended 30 June were ¥1 million. There were no material changes in the status of the Group's R&D activities during the three months ended 30 June.」
R&D expenses were ¥1 million, and there were no material changes in the status of R&D activities. - FY2017-Q3First statedAnnual report
「Total R&D expenses for the nine months ended 31 December were ¥4 million. There were no material changes in the status of the Group's R&D activities during the nine months ended 31 December.」
Total R&D expenses for the nine months ended 31 December were ¥4 million, and there were no material changes in the status of R&D activities.